CNS Pharma targets oncology, neurology in-licensing to build new therapy pipeline
CNSP•CNS Pharmaceuticals outlines pipeline-building strategy
CNS Pharmaceuticals outlined a strategy to build a pipeline in oncology or neurology, targeting assets with best-in-class potential.
Its near-term focus is on executing business development plans through in-licensing or acquisitions to expand its portfolio.
The screening process prioritizes scientific, clinical, regulatory and commercial fit to support long-term shareholder value creation.
